Star Therapeutics
Scott Robertson is a seasoned executive with extensive experience in business development and finance within the biopharma and agricultural sectors. Currently serving as the Chief Business Officer and Chief Financial Officer at Star Therapeutics since January 2024 and as a Board Member and Audit Committee Chair at Bicara Therapeutics since October 2023, Scott has also held significant roles at DICE Therapeutics, including Chief Business & Financial Officer during its acquisition by Eli Lilly & Company. Prior to that, Scott was a lecturer at the University of California, Berkeley, Haas School of Business since July 2015, and served on the board of Hexima Limited, where responsibilities included chairing the Compensation Committee and participating in the Audit Committee. Previous experience encompasses leading M&A and business development efforts at DuPont, as well as venture capital roles at MPM Capital and Merrill Lynch. Scott holds an MBA from the University of Southern California and has a degree from the University of California, Berkeley, Haas School of Business.
This person is not in any teams
This person is not in any offices
Star Therapeutics
Star Therapeutics is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need. Our innovation engine starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy. Star consists of a family of companies, each focusing on a specific area of novel biology and developing first-in-class antibody therapeutics. Electra Therapeutics, the first company within our portfolio to be unveiled, is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.
Employees
11-50